{
  "question_stem": {
    "en": "A 34-year-old man comes to the office due to severe fatigue. The patient was diagnosed with paroxysmal nocturnal hemoglobinuria 3 years ago, and he has required several blood transfusions due to anemia. Treatment is initiated with a monoclonal antibody that prevents formation of the protein complex leading to hemolysis in this patient.",
    "zh": "一名34岁男性因严重疲劳前来就诊。患者于3年前被诊断为阵发性睡眠性血红蛋白尿症，并且由于贫血需要多次输血。治疗开始使用单克隆抗体，该抗体可阻止导致该患者溶血的蛋白复合物的形成。"
  },
  "question": {
    "en": "Prophylactic pharmacotherapy will be required to prevent infection by which of the following organisms?",
    "zh": "需要预防性药物治疗以预防下列哪种病原体引起的感染？"
  },
  "options": {
    "A": {
      "en": "Haemophilus influenzae nontypable",
      "zh": "非典型流感嗜血杆菌"
    },
    "B": {
      "en": "Mycobacterium tuberculosis",
      "zh": "结核分枝杆菌"
    },
    "C": {
      "en": "Neisseria meningitidis",
      "zh": "脑膜炎奈瑟菌"
    },
    "D": {
      "en": "Staphylococcus aureus",
      "zh": "金黄色葡萄球菌"
    },
    "E": {
      "en": "Streptococcus pyogenes",
      "zh": "化脓性链球菌"
    }
  },
  "correct_answer": "C",
  "explanation": {
    "en": "Paroxysmal nocturnal hemoglobinuria (PNH) is caused by a mutation in hematologic stem cells that eliminates production of an anchoring protein that attaches surface molecules to the cell membrane. Loss of this membrane anchor prevents erythrocytes from expressing the complement-inactivating surface proteins CD55 and CD59. Without these surface proteins, autoactivated components of the alternative complement cascade cannot be disabled. This leads to spontaneous complement amplification, the generation of membrane attack complexes (MACs) on the red cell membrane, and subsequent complement-mediated hemolysis.\n\nTreatment with a monoclonal antibody (eg, eculizumab) that targets C5, the first complement protein that contributes to the formation of MACs, can drastically reduce hemolysis and improve symptoms (eg, fatigue) in patients with PNH. However, the generation of MACs is crucial for defense against encapsulated organisms (eg, Neisseria meningitidis, Streptococcus pneumoniae) because these pathogens are resistant to other host defense mechanisms (eg, immunoglobulin binding, phagocytosis).\n\nPatients receiving anti-C5 therapy require vaccination against encapsulated pathogens (N meningitidis, S pneumoniae) and appropriate antibiotic prophylaxis (eg, penicillin) to prevent fulminant infection.\n\n(Choice A) Nontypable strains of Haemophilus influenzae are not encapsulated; therefore, these strains are susceptible to phagocytosis and immunoglobulin-mediated opsonization. Control is not primarily mediated by the formation of MACs.\n\n(Choice B) Host defense to Mycobacterium tuberculosis depends more on T-cell and antigen-presenting cells than on complement activation and MAC formation.\n\n(Choices D and E) Staphylococcus aureus and Streptococcus pyogenes often secrete factors that disable the complement cascade. Therefore, they are primarily countered by other components of the immune system (eg, neutrophils, humoral immunity).\n\nEducational objective:\nParoxysmal nocturnal hemoglobinuria leads to the formation of membrane attack complexes on erythrocytes. Treatment with monoclonal antibody against C5, the first component of the membrane attack complex, can improve symptoms. However, it also increases risk for encapsulated bacterial infection. Therefore, patients require vaccination and antibiotic prophylaxis against Neisseria meningitidis and Streptococcus pneumoniae.",
    "zh": "阵发性睡眠性血红蛋白尿症（PNH）是由造血干细胞的突变引起的，该突变消除了将表面分子附着到细胞膜上的锚定蛋白的产生。这种膜锚的缺失阻止了红细胞表达补体失活表面蛋白CD55和CD59。如果没有这些表面蛋白，替代补体级联反应的自激活成分就无法被禁用。这导致自发性补体扩增，红细胞膜上膜攻击复合物（MACs）的产生，以及随后的补体介导的溶血。\n\n使用靶向C5（有助于MACs形成的第一个补体蛋白）的单克隆抗体（例如依库丽单抗）治疗可以显着减少PNH患者的溶血并改善症状（例如疲劳）。然而，MACs的产生对于防御荚膜病原体（例如，脑膜炎奈瑟菌，肺炎链球菌）至关重要，因为这些病原体对其他宿主防御机制（例如，免疫球蛋白结合，吞噬作用）具有抵抗力。\n\n接受抗C5治疗的患者需要接种针对荚膜病原体（脑膜炎奈瑟菌，肺炎链球菌）的疫苗，并进行适当的抗生素预防（例如青霉素），以防止暴发性感染。\n\n(选项A)非典型流感嗜血杆菌菌株没有荚膜；因此，这些菌株容易受到吞噬作用和免疫球蛋白介导的调理作用。控制并非主要由MACs的形成介导。\n\n(选项B)宿主对结核分枝杆菌的防御更多地依赖于T细胞和抗原呈递细胞，而不是补体激活和MAC形成。\n\n(选项D和E)金黄色葡萄球菌和化脓性链球菌经常分泌使补体级联反应失活的因子。因此，它们主要受到免疫系统的其他成分的对抗（例如，中性粒细胞，体液免疫）。\n\n教学目标：\n阵发性睡眠性血红蛋白尿症导致红细胞上形成膜攻击复合物。使用针对C5（膜攻击复合物的第一个成分）的单克隆抗体治疗可以改善症状。然而，它也增加了荚膜细菌感染的风险。因此，患者需要接种针对脑膜炎奈瑟菌和肺炎链球菌的疫苗，并进行抗生素预防。"
  },
  "summary": {
    "en": "This question tests knowledge of paroxysmal nocturnal hemoglobinuria (PNH) and the mechanism of action of eculizumab, a monoclonal antibody that inhibits the complement cascade. It also assesses understanding of the increased risk of encapsulated bacterial infections in patients treated with eculizumab.\n\nThe key to solving this question is recognizing that eculizumab inhibits the formation of membrane attack complexes (MACs), which are crucial for defense against encapsulated organisms. Therefore, patients receiving eculizumab require vaccination and antibiotic prophylaxis against encapsulated pathogens like Neisseria meningitidis and Streptococcus pneumoniae.",
    "zh": "这个问题测试了对阵发性睡眠性血红蛋白尿症（PNH）以及依库丽单抗（一种抑制补体级联反应的单克隆抗体）的作用机制的了解。它还评估了对使用依库丽单抗治疗的患者中荚膜细菌感染风险增加的理解。\n\n解决这个问题的关键是认识到依库丽单抗抑制膜攻击复合物（MACs）的形成，MACs对防御荚膜生物至关重要。因此，接受依库丽单抗治疗的患者需要接种疫苗并进行抗生素预防，以预防脑膜炎奈瑟菌和肺炎链球菌等荚膜病原体。"
  },
  "tags": "Paroxysmal nocturnal hemoglobinuria; Eculizumab; Complement system; Membrane attack complex; Encapsulated bacteria; Neisseria meningitidis; Streptococcus pneumoniae; Hematology; Infectious diseases; Meningococci",
  "category": "Micro",
  "question_id": "18594",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Micro 23\\18594",
  "extracted_at": "2025-11-05T15:02:20.025733",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:10:33.125431",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}